Capping bioprosthetic tissue to reduce calcification

Patent metadata

Field	Value
Publication number	US-9029418-B2
Application number	US-201314139367-A
Country	US
Kind code	B2
Filing date	Dec 23, 2013
Priority date	Dec 21, 2007
Publication date	May 12, 2015
Grant date	May 12, 2015

Abstract

A treatment for bioprosthetic tissue used in implants or for assembled bioprosthetic heart valves to reduce in vivo calcification. The method includes applying a calcification mitigant such as a capping agent or an antioxidant to the tissue to specifically inhibit oxidation in tissue. Also, the method can be used to inhibit oxidation in dehydrated tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the oxidation and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. In one method, tissue leaflets in assembled bioprosthetic heart valves are pretreated with an aldehyde capping agent prior to dehydration and sterilization.

First claim

The invention claimed is:

1. A method for mitigating calcification in a bioprosthetic tissue, the method comprising:
at least partially cross-linking the bioprosthetic tissue;
treating the bioprosthetic tissue with a capping agent, wherein the capping agent reacts with functional groups associated with the bioprosthetic tissue; and
treating the bioprosthetic tissue with a reducing agent, wherein the reducing agent reduces any Schiff bases created by the reaction of the capping…

Assignees

• Edwards Lifesciences Corp

Inventors

• Dove Jeffrey S
• Dobler Darin P
• Davidson James A
• Wright Gregory A

Classifications

• A61L2400/02

  Human Necessities · mapped topic

• A61F2/24

  Human Necessities · mapped topic

• A61L27/3604 Primary

  Human Necessities · mapped topic

• A61L27/3687 Primary

  Human Necessities · mapped topic

• A61L27/507

  Human Necessities · mapped topic